The FDA's recent guidelines encouraging pharmacogenomics appear to be drawing the interest of large pharmaceutical companies interested in the groundwork already begun by small biotech companies. Industry officials and analysts see the guidelines as a particular help to small companies such as Celera Genomics and deCode, two of the industry leaders in mapping the human genome and specific populations.

Full Story:

Related Summaries